Merus' Antibody Candidate In Phase II Breast Cancer Study
Zacks Investment Research | Jan 28, 2018 09:50PM ET
Merus N.V. (NASDAQ:MRUS) announced that it has initiated a phase II study to evaluate its most advanced bispecific antibody candidate, MCLA-128, in patients with metastatic breast cancer (“MBC”).
The study comprises two cohorts. The first cohort will evaluate a combination of MCLA-128, Roche’s (OTC:RHHBY) Herceptin and chemotherapy in MBC patients who are HER2-positive and their disease have progressed after treating with anti-HER2 therapies. The second cohort will evaluate MCLA-128 in combination with endocrine therapy in patients with HR+/HER2-low MBC and whose disease has progressed after treatment with hormone therapies and CDK4/6 inhibitors.
Merus’ shares have increased 15% in the past six months, comparing favorably with the industry ’s gain of 2.5% in that period.
Data from pre-clinical study demonstrated that the candidate has shown synergy with Herceptin in blocking heregulin-driven tumor cell growth and blocking of signaling through the HER3 pathway with endocrine therapy as well.
The primary endpoint of the study is to achieve clinical benefit (Complete Response, Partial Response or Stable Disease) at 24-weeks in both the arms. The study will also evaluate progression free survival, overall survival, duration of response and overall response rate among others as its secondary endpoints.
The company is also developing MCLA-128 in early stage studies as a treatment for gastric, ovarian, endometrial and NSCL cancers. Apart from MCLA-128, Merus is also developing another bispecific antibody candidate, MCLA-117, in acute myeloid leukemia.
However, the breast cancer segment is getting lot interest from other large as well as small cap pharma companies. We note that earlier this month, the FDA approved line extension of AstraZeneca’s (NYSE:AZN) PARP inhibitor, Lynparza, to include MBC.
Merus has no approved product in its portfolio. However, it earns revenues as part of its research agreement with Japan-based ONO Pharmaceuticals and collaboration and license agreement with Incyte Corporation (NASDAQ:INCY) .
Merus N.V. Price
Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.